Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia's Pharmaceutical Benefits Scheme Puts Damper On Roche's Avastin Sales

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Sales of the top 20 cancer drugs in Australia totaled $545 million in 2008, representing a growth rate of 30 percent since 2005, according to a recent Datamonitor report

You may also be interested in...



New Zealand Ministry Of Health Overturns PHARMAC Decision To Decline Funding Roche 12-Month Herceptin Treatment: New Zealand Regulatory Roundup

PERTH, Australia - After much heated debate, New Zealand's newly elected National Party has overturned the Pharmaceutical Management Agency's decision to decline funding for 12-month treatment of Roche's Herceptin (trastuzumab) for HER2-positive early breast cancer treatment

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

SC074289

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel